ClinicalTrials.Veeva
Menu

Find clinical trials for Adenocarcinoma in Houston, TX

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Carcinoma
Cancer
Pancreatic Cancer
Colorectal Cancer
Stomach Cancer
Esophageal Cancer
Non-Small-Cell Lung Carcinoma

Adenocarcinoma trials near Houston, TX, USA:

A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (AndroMETa-GEA)

metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEA).ABBV-400 and Budigalimab are investigational drugs being...

Enrolling
Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma
Esophageal Adenocarcinoma
Drug: Budigalimab
Drug: ABBV-400

Phase 2

AbbVie
AbbVie

Houston, Texas, United States and 8 other locations

Exploratory Platform Trial to Evaluate Immunotherapy Combinations With Chemotherapy for the Treatment of Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma (REVOLUTION)

to evaluate the safety and efficacy of first-line chemo-immunotherapy combinations in participants with metastatic pancreatic ductal adenocarcinoma...

Active, not recruiting
Metastatic Pancreatic Adenocarcinoma
Drug: NG350A (Cohort C)
Drug: Nab-paclitaxel (nP) (Cohort A, B and C)

Phase 1

Cancer Insight

Houston, Texas, United States and 5 other locations

Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer

cancer Trial Phase: Phase II Clinical Indication: Pancreatic ductal adenocarcinoma; Adenocarcinoma; AJCC I, II, or III; 1st Line ne...

Enrolling
Pancreatic Ductal Adenocarcinoma
Drug: Pembrolizumab
Drug: Folfirinox

Phase 2

Baylor College of Medicine
Baylor College of Medicine

Houston, Texas, United States and 2 other locations

PT886 for Treatment of Patients with Metastatic/Advanced Gastric, Gastroesophageal Junction and Pancreatic Adenocarcinoma (the TWINPEAK Study)

will be eligible for screening: unresectable or metastatic gastric adenocarcinoma, gastroesophageal junction (GEJ) adenocarcinoma, ...

Enrolling
Pancreatic Ductal Adenocarcinoma
Gastric or Gastroesophageal Junction Adenocarcinoma
Drug: FOLFIRINOX
Drug: KEYTRUDA® (pembrolizumab)

Phase 1, Phase 2

Phanes Therapeutics

Houston, Texas, United States and 5 other locations

Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic Adenocarcinoma

This study is an open-label, phase 1/1b study of the pressure-enabled intrapancreatic infusion of SD-101, a TLR 9 agonist, alone or in combination wi...

Enrolling
Locally Advanced Pancreatic Adenocarcinoma
Drug: SD-101
Biological: anti-PD-1

Phase 1

TriSalus Life Sciences

Houston, Texas, United States

A Study of Ivaltinostat Plus Capecitabine or Capecitabine in Metastatic Pancreatic Adenocarcinoma

and capecitabine monotherapy in patients with metastatic pancreatic adenocarcinoma whose disease has not progressed on a first line fluoropy...

Enrolling
Metastatic Pancreatic Adenocarcinoma
Drug: Capecitabine
Drug: Ivaltinostat

Phase 1, Phase 2

CG Pharmaceuticals

Houston, Texas, United States and 15 other locations

A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer (DisTinGuish)

as First-Line or Second-Line Therapy in Adult Patients with Inoperable, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma...

Active, not recruiting
Gastric Adenocarcinoma
Gastric Cancer
Drug: Tislelizumab 200mg
Drug: DKN-01 400mg

Phase 2

Leap Therapeutics

Houston, Texas, United States and 47 other locations

A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW)

The purpose of this study is to evaluate the efficacy of zolbetuximab plus capecitabine and oxaliplatin (CAPOX) compared with placebo plus CAPOX (as...

Active, not recruiting
Metastatic Gastric Adenocarcinoma or Cancer
Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer
Drug: placebo
Drug: oxaliplatin

Phase 3

Astellas
Astellas

Houston, Texas, United States and 164 other locations

A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer

adenocarcinoma (GEA), biliary tract cancer (BTC), or colorectal cancer (CRC)....

Active, not recruiting
HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
Drug: Oxaliplatin
Drug: Fluorouracil

Phase 2

Jazz Pharmaceuticals
Jazz Pharmaceuticals

Houston, Texas, United States and 20 other locations

A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma

participants with platinum-resistant ovarian carcinoma, endometrial adenocarcinoma, and urothelial carcinoma based on Acrivon's OncoSignatur...

Enrolling
Endometrial Adenocarcinoma
Urothelial Carcinoma
Diagnostic Test: OncoSignature
Drug: ACR-368

Phase 1, Phase 2

Acrivon Therapeutics

Houston, Texas, United States and 66 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2025 Veeva Systems